Mallinckrodt Announces Interim Analysis Results For Therakos Platform Phase 3 Clinical Trial In Treatment Of Pediatric Patients With Steroid Refractory Acute Graft-versus-Host Disease; Overall Response Rate Exceeded Specified Study Midpoint Target
Benzinga Newsdesk